$INO
INOVIO PHARMACEUTICALS, INC.

2024 Q4 Form 10-Q Financial Statement

#000105572624000052 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.614M
YoY Change -13.25%
% of Gross Profit
Research & Development $18.73M
YoY Change 20.84%
% of Gross Profit
Depreciation & Amortization $419.3K
YoY Change -34.48%
% of Gross Profit
Operating Expenses $27.35M
YoY Change -23.91%
Operating Profit -$27.35M
YoY Change -23.08%
Interest Expense $2.762M
YoY Change 781.0%
% of Operating Profit
Other Income/Expense, Net -$579.8K
YoY Change -20416.01%
Pretax Income -$25.17M
YoY Change -25.83%
Income Tax
% Of Pretax Income
Net Earnings -$25.17M
YoY Change -25.77%
Net Earnings / Revenue
Basic Earnings Per Share -$0.89
Diluted Earnings Per Share -$0.89
COMMON SHARES
Basic Shares Outstanding 26.10M shares 25.96M shares
Diluted Shares Outstanding 28.14M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.80M
YoY Change -49.37%
Cash & Equivalents $21.69M
Short-Term Investments $63.12M
Other Short-Term Assets $4.617M
YoY Change -9.47%
Inventory
Prepaid Expenses
Receivables $1.863M
Other Receivables $0.00
Total Short-Term Assets $91.28M
YoY Change -47.77%
LONG-TERM ASSETS
Property, Plant & Equipment $4.092M
YoY Change -27.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.644M
YoY Change -11.86%
Other Assets $566.4K
YoY Change -6.43%
Total Long-Term Assets $15.78M
YoY Change -13.94%
TOTAL ASSETS
Total Short-Term Assets $91.28M
Total Long-Term Assets $15.78M
Total Assets $107.1M
YoY Change -44.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.386M
YoY Change 38.09%
Accrued Expenses $18.11M
YoY Change -7.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $23.50M
YoY Change -46.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $10.02M
YoY Change -10.53%
Total Long-Term Liabilities $10.02M
YoY Change -10.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.50M
Total Long-Term Liabilities $10.02M
Total Liabilities $33.52M
YoY Change -38.99%
SHAREHOLDERS EQUITY
Retained Earnings -$1.700B
YoY Change 6.25%
Common Stock $26.05K
YoY Change -90.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $73.54M
YoY Change
Total Liabilities & Shareholders Equity $107.1M
YoY Change -44.56%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$25.17M
YoY Change -25.77%
Depreciation, Depletion And Amortization $419.3K
YoY Change -34.48%
Cash From Operating Activities -$27.44M
YoY Change -5.73%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $14.08M
YoY Change -355.96%
Cash From Investing Activities $14.08M
YoY Change -355.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 660.6K
YoY Change -5.62%
NET CHANGE
Cash From Operating Activities -27.44M
Cash From Investing Activities 14.08M
Cash From Financing Activities 660.6K
Net Change In Cash -12.70M
YoY Change -62.53%
FREE CASH FLOW
Cash From Operating Activities -$27.44M
Capital Expenditures $0.00
Free Cash Flow -$27.44M
YoY Change -5.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001055726
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0969592
dei Entity Address Address Line1
EntityAddressAddressLine1
660 W. Germantown Pike
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
267
dei Local Phone Number
LocalPhoneNumber
440-4200
dei Security12b Title
Security12bTitle
COMMON STOCK, $0.001 PAR VALUE
dei Trading Symbol
TradingSymbol
INO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26099991 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21687480 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14310862 usd
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
63117288 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-25165478 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-98089766 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
174250213 usd
dei Entity Registrant Name
EntityRegistrantName
INOVIO PHARMACEUTICALS, INC.
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1862739 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2405228 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4617116 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5393665 usd
CY2024Q3 ino Prepaid Expenses And Other Current Assets From Affiliated Entity
PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
0 usd
CY2023Q4 ino Prepaid Expenses And Other Current Assets From Affiliated Entity
PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
20432 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
91284623 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
153113100 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4091562 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4960986 usd
CY2024Q3 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
2644226 usd
CY2023Q4 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
2780287 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9491735 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
566415 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
605315 usd
CY2024Q3 us-gaap Assets
Assets
107059674 usd
CY2023Q4 us-gaap Assets
Assets
170951423 usd
CY2024Q3 ino Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
4496568 usd
CY2023Q4 ino Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
2365382 usd
CY2024Q3 ino Deferred Grant Funding Current
DeferredGrantFundingCurrent
0 usd
CY2023Q4 ino Deferred Grant Funding Current
DeferredGrantFundingCurrent
87489 usd
CY2024Q3 ino Deferred Grant Funding From Affiliate Current
DeferredGrantFundingFromAffiliateCurrent
0 usd
CY2023Q4 ino Deferred Grant Funding From Affiliate Current
DeferredGrantFundingFromAffiliateCurrent
21918 usd
CY2024Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0 usd
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
16770654 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42570228 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10020227 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11032066 usd
CY2024Q3 us-gaap Liabilities
Liabilities
33519364 usd
CY2023Q4 us-gaap Liabilities
Liabilities
53602294 usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
26051 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
22792 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1784975303 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1740954074 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1710837583 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1622965136 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-623461 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-662601 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
73540310 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
117349129 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107059674 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170951423 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
388446 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8472848 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2425112 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2406522 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
100762 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
729359 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18733584 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15503032 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62734891 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69423513 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8613895 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9925055 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29395232 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37338763 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22385229 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22385229 shares
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083333
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083333
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.083333
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
130982913 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23499137 usd
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
10513371 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
10513371 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
27347479 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
35941458 usd
us-gaap Operating Expenses
OperatingExpenses
92130123 usd
us-gaap Operating Expenses
OperatingExpenses
117275647 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27347479 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-35553012 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-92029361 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-116546288 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1106758 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1938745 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3914406 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
6314149 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
0 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
313488 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
177833 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
940464 usd
CY2024Q3 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
324251 usd
CY2023Q3 ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
214374 usd
ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-136061 usd
ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
987758 usd
CY2024Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1330811 usd
CY2023Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-219337 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1810868 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
3921819 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-579819 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2854 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1254466 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3850688 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-25165478 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33929864 usd
us-gaap Net Income Loss
NetIncomeLoss
-87872447 usd
us-gaap Net Income Loss
NetIncomeLoss
-110113714 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28140497 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28140497 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26216983 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26216983 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21986840 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21986840 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33929864 usd
us-gaap Net Income Loss
NetIncomeLoss
-87872447 usd
us-gaap Net Income Loss
NetIncomeLoss
-110113714 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2109 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32403 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4403 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
66075 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-57703 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6737 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47930 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25099403 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33989676 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-87833307 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-110166047 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
117349129 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5225133 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-174248 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2525433 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-30469871 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-46016 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32403 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
94441963 usd
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
17059668 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
16146397 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-172454 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1514053 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-32237098 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13322 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
96739207 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
667066 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-6418 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1239858 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-25165478 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
66075 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
73540310 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
222362756 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14000000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-424704 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3809003 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-40649317 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
117862 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1918 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
199213682 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2915179 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-32292 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2917997 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-35534533 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108089 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-376 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
169371568 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
708283 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-9650 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2079188 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33929864 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-57703 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2109 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
138159713 usd
us-gaap Net Income Loss
NetIncomeLoss
-87872447 usd
us-gaap Net Income Loss
NetIncomeLoss
-110113714 usd
us-gaap Depreciation
Depreciation
1335326 usd
us-gaap Depreciation
Depreciation
2051962 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
145417 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1018887 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1130932 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
10513371 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1984444 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5279344 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8806188 usd
ino Non Cash Interest Income Expense
NonCashInterestIncomeExpense
355654 usd
ino Non Cash Interest Income Expense
NonCashInterestIncomeExpense
126511 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1510276 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3641765 usd
us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
-1278959 usd
us-gaap Gain Loss On Sale Of Other Investments
GainLossOnSaleOfOtherInvestments
-3853691 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-21930 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-364422 usd
ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
-136061 usd
ino Change In Value Of Investments In Affiliated Company
ChangeInValueOfInvestmentsInAffiliatedCompany
987758 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1810868 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
3921819 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-542489 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9594021 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-796981 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39285174 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-38900 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-78729 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4340806 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-50641862 usd
ino Increase Decrease In Accrued Clinical Trial Expense
IncreaseDecreaseInAccruedClinicalTrialExpense
2131186 usd
ino Increase Decrease In Accrued Clinical Trial Expense
IncreaseDecreaseInAccruedClinicalTrialExpense
-5582888 usd
ino Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
-993249 usd
ino Increase Decrease In Operating Lease Right Of Use Asset Lease Liability Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
-2147175 usd
ino Increase Decreasein Deferred Grant Funding Current
IncreaseDecreaseinDeferredGrantFundingCurrent
-109407 usd
ino Increase Decreasein Deferred Grant Funding Current
IncreaseDecreaseinDeferredGrantFundingCurrent
1265375 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84412644 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
54138027 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
124052574 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
235912707 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
487832 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
320898 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6071000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
69426715 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67412596 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
16415000 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
16146397 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
22951867 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3623462 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67675 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
ino Proceeds From Payments For Stock Options Exercised And Exercise Of Warrants Net Of Tax Withholdings
ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings
-420795 usd
ino Proceeds From Payments For Stock Options Exercised And Exercise Of Warrants Net Of Tax Withholdings
ProceedsFromPaymentsForStockOptionsExercisedAndExerciseOfWarrantsNetOfTaxWithholdings
-466646 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22330144 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3156816 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32403 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4403 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7376618 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27524757 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14310862 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46329359 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21687480 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18804602 usd
us-gaap Interest Paid Net
InterestPaidNet
533487 usd
us-gaap Interest Paid Net
InterestPaidNet
1066975 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Stock Issued1
StockIssued1
14000000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the “Company” or “INOVIO”) is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">INOVIO uses proprietary technology to design DNA plasmids, which are small circular DNA molecules that work like software the body’s cells can download to produce specific proteins to target and fight disease. The Company's proprietary investigational CELLECTRA delivery devices are designed to optimally deliver the plasmids into the body's cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a life-long, rare disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following administration of INO-3107, when compared with the year prior to treatment. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to its development efforts with INO-3107, INOVIO is actively developing or planning to develop DNA medicines for other indications, including HPV-related oropharyngeal squamous cell carcinoma (OPSCC) and anal dysplasia; glioblastoma multiforme (GBM), a deadly form of brain cancer; and a potential vaccine booster to protect against the Ebola virus. The Company was previously conducting clinical trials of a DNA medicine candidate for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions (HSIL) but announced in August 2023 that it was ceasing development for this indication in the United States. However, its collaborator ApolloBio Corporation continues to conduct a Phase 3 clinical trial of this candidate in China and plans to seek regulatory approval for and potentially commercialize the candidate in that jurisdiction. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Coherus Biosciences, Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div>
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-25200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-87900000 usd
CY2024Q3 ino Working Capital
WorkingCapital
67800000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1700000000 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
84800000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
65190198 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
27241 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2100151 usd
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
63117288 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
134873427 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
36647 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3927161 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
130982913 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
200 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
700 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
587000 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
1300000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
300 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
800 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
500 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
3900000 usd
CY2024Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1300000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1800000 usd
CY2023Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-219000 usd
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
3900000 usd
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
19 position
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-2100000 usd
CY2024Q3 ino Prepaid Clinical Expenses Current
PrepaidClinicalExpensesCurrent
2264051 usd
CY2023Q4 ino Prepaid Clinical Expenses Current
PrepaidClinicalExpensesCurrent
3410442 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2353065 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1983223 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4617116 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5393665 usd
CY2024Q3 ino Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
95000 usd
CY2023Q4 ino Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
1500000 usd
ino Grant Liability
GrantLiability
0 usd
CY2023 ino Grant Liability
GrantLiability
4300000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26052452 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26052452 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22793075 shares
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-25165478 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-33929864 usd
CY2024Q3 ino Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
26005020 shares
CY2023Q3 ino Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
22385229 shares
CY2024Q3 ino Incremental Common Shares Attributable To Basic And Dilutive Effect Of Pre Funded Warrants
IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants
2135477 shares
CY2023Q3 ino Incremental Common Shares Attributable To Basic And Dilutive Effect Of Pre Funded Warrants
IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants
0 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28140497 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28140497 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22385229 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22385229 shares
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.52
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
us-gaap Net Income Loss
NetIncomeLoss
-87872447 usd
us-gaap Net Income Loss
NetIncomeLoss
-110113714 usd
ino Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
24923227 shares
ino Weighted Average Number Of Shares Outstanding
WeightedAverageNumberOfSharesOutstanding
21986840 shares
ino Incremental Common Shares Attributable To Basic And Dilutive Effect Of Pre Funded Warrants
IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants
1293756 shares
ino Incremental Common Shares Attributable To Basic And Dilutive Effect Of Pre Funded Warrants
IncrementalCommonSharesAttributableToBasicAndDilutiveEffectOfPreFundedWarrants
0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26216983 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26216983 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21986840 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21986840 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.01
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1729952 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1729952 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1741869 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1741869 shares
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2800000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.01
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.28
ino Share Based Compensation Arrangement By Share Based Payment Award Threshold Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPercentage
1.50
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
873000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3483000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3555000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2955000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2310000 usd
CY2024Q3 ino Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
2132000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15308000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2863000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
12445000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2425000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10020000 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2024Q3 us-gaap Lease Cost
LeaseCost
662000 usd
us-gaap Lease Cost
LeaseCost
2000000.0 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
851000 usd
us-gaap Lease Cost
LeaseCost
2500000 usd
CY2019Q4 ino Lessee Operating Lease Number Of Agreements To Sublease
LesseeOperatingLeaseNumberOfAgreementsToSublease
2 agreement
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001055726-24-000052-index-headers.html Edgar Link pending
0001055726-24-000052-index.html Edgar Link pending
0001055726-24-000052.txt Edgar Link pending
0001055726-24-000052-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ino-20240930.htm Edgar Link pending
ino-20240930.xsd Edgar Link pending
ino-20240930_g1.jpg Edgar Link pending
ino-9302410qex312.htm Edgar Link pending
ino-93024x10qex311.htm Edgar Link pending
ino-93024x10qex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
ino-20240930_cal.xml Edgar Link unprocessable
ino-20240930_def.xml Edgar Link unprocessable
ino-20240930_lab.xml Edgar Link unprocessable
ino-20240930_pre.xml Edgar Link unprocessable
ino-20240930_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable